Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.25
0.075.93%
At close: -
$1.23
-0.02-1.60%
After Hours: 6:56 PM EDT
Comments
Loading...
Acrivon Therapeutics Analyst Ratings and Price Targets | NASDAQ:ACRV | Benzinga
Acrivon Therapeutics Inc has a consensus price target of $20.2 based on the ratings of 13 analysts. The high is $30 issued by Piper Sandler on April 25, 2024. The low is $9 issued by Oppenheimer on May 15, 2025. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and Citizens Capital Markets on May 15, 2025, March 28, 2025, and March 26, 2025, respectively. With an average price target of $15 between Oppenheimer, HC Wainwright & Co., and Citizens Capital Markets, there's an implied 1119.51% upside for Acrivon Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Citizens Capital Markets
BMO Capital
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Acrivon Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | — | Jones Trading | Soumit Roy33% | — | Downgrade | Buy → Hold | Get Alert |
| 05/15/2025 | Buy Now | 631.71% | Oppenheimer | Matthew Biegler37% | $10 → $9 | Maintains | Outperform | Get Alert |
| 03/28/2025 | Buy Now | 1444.72% | HC Wainwright & Co. | Emily Bodnar36% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2025 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/26/2025 | Buy Now | 1282.11% | Citizens Capital Markets | Silvan Tuerkcan46% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/26/2025 | Buy Now | 1444.72% | HC Wainwright & Co. | Emily Bodnar36% | $22 → $19 | Maintains | Buy | Get Alert |
| 01/31/2025 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | — | Initiates | → Overweight | Get Alert |
| 11/14/2024 | Buy Now | 2095.12% | BMO Capital | Etzer Darout44% | $28 → $27 | Maintains | Outperform | Get Alert |
| 11/14/2024 | Buy Now | 1688.62% | HC Wainwright & Co. | Emily Bodnar36% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 1282.11% | JMP Securities | Silvan Tuerkcan46% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/16/2024 | Buy Now | 1200.81% | Ladenburg Thalmann | Aydin Huseynov33% | → $16 | Upgrade | Neutral → Buy | Get Alert |
| 09/16/2024 | Buy Now | 2176.42% | BMO Capital | Etzer Darout44% | $25 → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 09/16/2024 | Buy Now | 1688.62% | HC Wainwright & Co. | Emily Bodnar36% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 1688.62% | HC Wainwright & Co. | Emily Bodnar36% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 1932.52% | BMO Capital | Etzer Darout44% | $25 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 05/14/2024 | Buy Now | 1688.62% | HC Wainwright & Co. | Emily Bodnar36% | $20 → $22 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | — | Ladenburg Thalmann | Aydin Huseynov33% | — | Downgrade | Buy → Neutral | Get Alert |
| 04/26/2024 | Buy Now | 1932.52% | BMO Capital | Etzer Darout44% | $18 → $25 | Maintains | Outperform | Get Alert |
| 04/25/2024 | Buy Now | 1526.02% | HC Wainwright & Co. | Emily Bodnar36% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 1282.11% | JMP Securities | Silvan Tuerkcan46% | $14 → $17 | Maintains | Market Outperform | Get Alert |
| 04/25/2024 | Buy Now | 2339.02% | Piper Sandler | Joseph Catanzaro43% | $26 → $30 | Maintains | Overweight | Get Alert |
| 04/05/2024 | Buy Now | 1038.21% | Ladenburg Thalmann | Aydin Huseynov33% | $18 → $14 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | 1038.21% | JMP Securities | Silvan Tuerkcan46% | $14 → $14 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/01/2024 | Buy Now | 1363.41% | BMO Capital | Etzer Darout44% | → $18 | Reiterates | Outperform → Outperform | Get Alert |
| 03/28/2024 | Buy Now | 1526.02% | HC Wainwright & Co. | Emily Bodnar36% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 1038.21% | JMP Securities | Silvan Tuerkcan46% | → $14 | Initiates | → Market Outperform | Get Alert |
| 11/10/2023 | Buy Now | 1851.22% | BMO Capital | Etzer Darout44% | $25 → $24 | Maintains | Outperform | Get Alert |
| 10/05/2023 | Buy Now | 1851.22% | Maxim Group | Michael Okunewitch28% | → $24 | Initiates | → Buy | Get Alert |
| 09/06/2023 | Buy Now | 1526.02% | HC Wainwright & Co. | Emily Bodnar36% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/18/2023 | Buy Now | 2013.82% | JonesTrading | Soumit Roy33% | → $26 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | 1526.02% | HC Wainwright & Co. | Emily Bodnar36% | $21 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 1932.52% | Oppenheimer | Matthew Biegler37% | → $25 | Initiates | → Outperform | Get Alert |
| 05/08/2023 | Buy Now | 1932.52% | BMO Capital | Etzer Darout44% | → $25 | Initiates | → Outperform | Get Alert |
| 05/02/2023 | Buy Now | 1851.22% | HC Wainwright & Co. | Emily Bodnar36% | → $24 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 1851.22% | HC Wainwright & Co. | Emily Bodnar36% | → $24 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | — | Cowen & Co. | Joseph Thome26% | — | Initiates | → Outperform | Get Alert |
| 12/12/2022 | Buy Now | 1282.11% | Jefferies | Akash Tewari41% | → $17 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | 1932.52% | Piper Sandler | Joseph Catanzaro43% | → $25 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Acrivon Therapeutics (ACRV) stock?
The latest price target for Acrivon Therapeutics (NASDAQ:ACRV) was reported by Jones Trading on May 16, 2025. The analyst firm set a price target for $0.00 expecting ACRV to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?
The latest analyst rating for Acrivon Therapeutics (NASDAQ:ACRV) was provided by Jones Trading, and Acrivon Therapeutics downgraded their hold rating.
When was the last upgrade for Acrivon Therapeutics (ACRV)?
The last upgrade for Acrivon Therapeutics Inc happened on September 16, 2024 when Ladenburg Thalmann raised their price target to $16. Ladenburg Thalmann previously had a neutral for Acrivon Therapeutics Inc.
When was the last downgrade for Acrivon Therapeutics (ACRV)?
The last downgrade for Acrivon Therapeutics Inc happened on May 16, 2025 when Jones Trading changed their price target from N/A to N/A for Acrivon Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?
While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acrivon Therapeutics (ACRV) is trading at is $1.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
